“…There were eight case studies, 53–60 reporting on 12 individual cases. The majority of studies (72.1%) were conducted in the United States, 18,20–33,35–38,40–42,46–48,50,52,55,56,58,60 others were from Australia (11.6%), 34,39,49,51,57 Europe (4.7%), 44,45 and a single paper each from Canada, 59 France, 54 Italy, 19 Spain 53 and the United Kingdom 43 . Eighteen papers presented data from one of three larger studies: Impact of Personal Genomics (PGen) used longitudinal surveys with a cohort of 1648 consumers who had purchased 23andme (SNP array) or Pathway Genomics (undisclosed product); Scripps Genomic Health Initiative (SGHI) studied 2037 consumers who purchased “Health Compass”, a subsidised DTC‐GT produced by Navigenics, which provided genetic risk information for common diseases and offered in‐house genetic counselling; and Genomics: National Insights of Australians (Genioz) explored the views and experiences of the Australian public regarding DTC‐GT and includes surveys and consumer interviews.…”